Novo Nordisk Acquires Chinese Obesity Drug After CagriSema Trial Disappointment

The Danish pharmaceutical giant pivots strategically, securing global rights to UBT251 to compete with Eli Lilly's advanced treatments in the expanding weight-loss drug market.